Fruquintinib DDI Study With P-gp and BCRP Substrates
Fruquintinib DDI Study with P-gp and BCRP Substrates
Metastatic Colorectal Cancer
DRUG: Fruquintinib|DRUG: Dabigatran Etexilate|DRUG: Rosuvastatin
PK parameter for dabigatran and rosuvastatin: AUC0-t:, area under the plasma concentration-time curve from time 0 to time of the last measurable concentration, Day 1 to Day 13|PK parameter for dabigatran and rosuvastatin: AUC0-inf:, area under the plasma concentration-time curve from time 0 to infinity (if data permit), Day 1 to Day 13|PK parameter for dabigatran and rosuvastatin: Cmax:, maximum observed plasma concentration, Day 1 to Day 13
Incidence of AEs/SAEs, Any untoward medical occurrence associated with the use of study drug, Day 1 to Day 13|PK parameter of fruquintinib and metabolite M11: AUC0-t:, area under the plasma concentration-time curve from time 0 to time of the last measurable concentration, Day 1 Day 13|PK parameters of fruquintinib and metabolite M11: AUC0-inf:, area under the plasma concentration-time curve from time 0 to infinity (if data permit), Day 1 to Day 13|PK parameters of fruquintinib and metabolite M11: Cmax:, maximum observed plasma concentration, Day 1 to Day 13
A phase 1, open-label, 2-part, 2-period fixed-sequence study to evaluate the effect of Fruquintinib on the pharmacokinetics of Dabigatran Etexilate (A P-GP substrate) and Rosuvastatin (A BCRP substrate) in healthy subjects